MedTrace Logo

REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry

NCT05728775 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7188

Last updated 2025-08-26

No results posted yet for this study

Summary

The goal of this randomized controlled trial is to compare total intravenous anesthesia with remimazolam vs total intravenous anesthesia with propofol in moderate-to-high risk patients undergoing major elective noncardiac surgery under general anesthesia. The primary hypothesis is that total intravenous anesthesia with remimazolam can increase days alive and out of hospital at postoperative day 30 compared with total intravenous anesthesia with propofol.

Conditions

  • Anesthesia
  • Surgery-Complications

Interventions

DRUG

Remimazolam

Remimazolam is administered intravenously for induction and maintenance of general anesthesia.

DRUG

Propofol

Propofol is administered intravenously for induction and maintenance of general anesthesia.

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-03
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05728775 on ClinicalTrials.gov